not very convinced myself. I can see why Oventus is keen (distribution), but what's really in it for ONT. Are dentists really the best means to recommend and administer this device. What will training cost?
I may be wrong, and are happy to be proved wrong, but it did feel as though it was an initiative Dr Holmes (or someone else) liked because he was assisting a fellow entrepreneur. On reading the announcement it didn't seem to offer much to me as a (detached) shareholder.
ONT Price at posting:
$7.62 Sentiment: Hold Disclosure: Held